158 related articles for article (PubMed ID: 28139264)
1. Clinical and pathologic factors associated with subclinical spread of invasive melanoma.
Shin TM; Shaikh WR; Etzkorn JR; Sobanko JF; Margolis DJ; Gelfand JM; Chu EY; Elenitsas R; Miller CJ
J Am Acad Dermatol; 2017 Apr; 76(4):714-721. PubMed ID: 28139264
[TBL] [Abstract][Full Text] [Related]
2. Clinical factors associated with subclinical spread of in situ melanoma.
Shin TM; Etzkorn JR; Sobanko JF; Margolis DJ; Gelfand JM; Chu EY; Elenitsas R; Shaikh WR; Miller CJ
J Am Acad Dermatol; 2017 Apr; 76(4):707-713. PubMed ID: 28073583
[TBL] [Abstract][Full Text] [Related]
3. Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining for atypical intraepidermal melanocytic proliferation.
Etzkorn JR; Jew OS; Shin TM; Sobanko JF; Neal DE; Miller CJ
J Am Acad Dermatol; 2018 Dec; 79(6):1109-1116.e1. PubMed ID: 30003986
[TBL] [Abstract][Full Text] [Related]
4. Low recurrence rates for in situ and invasive melanomas using Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining: tissue processing methodology to optimize pathologic staging and margin assessment.
Etzkorn JR; Sobanko JF; Elenitsas R; Newman JG; Goldbach H; Shin TM; Miller CJ
J Am Acad Dermatol; 2015 May; 72(5):840-50. PubMed ID: 25774012
[TBL] [Abstract][Full Text] [Related]
5. Correlation Between Appropriate Use Criteria and the Frequency of Subclinical Spread or Reconstruction With a Flap or Graft for Melanomas Treated With Mohs Surgery With Melanoma Antigen Recognized by T Cells 1 Immunostaining.
Etzkorn JR; Sobanko JF; Shin TM; Elenitsas R; Chu EY; Gelfand JM; Margolis DJ; Newman JG; Goldbach H; Miller CJ
Dermatol Surg; 2016 Apr; 42(4):471-6. PubMed ID: 26990255
[TBL] [Abstract][Full Text] [Related]
6. The use of Mohs micrographic surgery (MMS) for melanoma in situ (MIS) of the trunk and proximal extremities.
Stigall LE; Brodland DG; Zitelli JA
J Am Acad Dermatol; 2016 Nov; 75(5):1015-1021. PubMed ID: 27473456
[TBL] [Abstract][Full Text] [Related]
7. Comparison of surgical margins for lentigo maligna versus melanoma in situ.
Kunishige JH; Doan L; Brodland DG; Zitelli JA
J Am Acad Dermatol; 2019 Jul; 81(1):204-212. PubMed ID: 31014825
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical staining of lentigo maligna during Mohs micrographic surgery using MART-1.
Kelley LC; Starkus L
J Am Acad Dermatol; 2002 Jan; 46(1):78-84. PubMed ID: 11756950
[TBL] [Abstract][Full Text] [Related]
9. Importance of vertical pathology of debulking specimens during Mohs micrographic surgery for lentigo maligna and melanoma in situ.
Iorizzo LJ; Chocron I; Lumbang W; Stasko T
Dermatol Surg; 2013 Mar; 39(3 Pt 1):365-71. PubMed ID: 23356872
[TBL] [Abstract][Full Text] [Related]
10. Treating melanoma in situ and lentigo maligna with Mohs micrographic surgery in Australia.
Foxton GC; Elliott TG; Litterick KA
Australas J Dermatol; 2019 Feb; 60(1):33-37. PubMed ID: 29932208
[TBL] [Abstract][Full Text] [Related]
11. Excision Margins for Melanoma In Situ on the Head and Neck.
Felton S; Taylor RS; Srivastava D
Dermatol Surg; 2016 Mar; 42(3):327-34. PubMed ID: 26866286
[TBL] [Abstract][Full Text] [Related]
12. Conventional surgery compared with slow Mohs micrographic surgery in the treatment of lentigo maligna: a retrospective study of 62 cases.
Hilari H; Llorca D; Traves V; Villanueva A; Serra-Guillén C; Requena C; Llombart B; Sanmartín O; Guillén C; Nagore E
Actas Dermosifiliogr; 2012 Sep; 103(7):614-23. PubMed ID: 22572575
[TBL] [Abstract][Full Text] [Related]
13. Comparison of MITF and Melan-A Immunohistochemistry During Mohs Surgery for Lentigo Maligna-Type Melanoma In Situ and Lentigo Maligna Melanoma.
Christensen KN; Hochwalt PC; Hocker TL; Roenigk RK; Brewer JD; Baum CL; Otley CC; Arpey CJ
Dermatol Surg; 2016 Feb; 42(2):167-75. PubMed ID: 26771682
[TBL] [Abstract][Full Text] [Related]
14. Mohs micrographically controlled surgery and the treatment of malignant melanoma.
Nagi C; O'Grady TC; Izadpanah A
Semin Oncol; 2002 Aug; 29(4):336-40. PubMed ID: 12170436
[TBL] [Abstract][Full Text] [Related]
15. Mohs micrographic surgery in the treatment of lentigo maligna and melanoma.
Temple CL; Arlette JP
J Surg Oncol; 2006 Sep; 94(4):287-92. PubMed ID: 16917877
[TBL] [Abstract][Full Text] [Related]
16. Factors Influencing General Dermatologists When Referring Patients With Head and Neck Melanoma for Mohs Micrographic Surgery: A Nationwide Cross-Sectional Survey.
Neill BC; Siscos SM; Bar AA; Seger EW; Latour E; Tolkachjov SN
Dermatol Surg; 2023 May; 49(5):451-455. PubMed ID: 36989088
[TBL] [Abstract][Full Text] [Related]
17. Mohs Micrographic Surgery Using MART-1 Immunostain in the Treatment of Invasive Melanoma and Melanoma In Situ.
Valentín-Nogueras SM; Brodland DG; Zitelli JA; González-Sepúlveda L; Nazario CM
Dermatol Surg; 2016 Jun; 42(6):733-44. PubMed ID: 27158886
[TBL] [Abstract][Full Text] [Related]
18. Staged excision for lentigo maligna and lentigo maligna melanoma: A retrospective analysis of 117 cases.
Hazan C; Dusza SW; Delgado R; Busam KJ; Halpern AC; Nehal KS
J Am Acad Dermatol; 2008 Jan; 58(1):142-8. PubMed ID: 18029055
[TBL] [Abstract][Full Text] [Related]
19. Immunostaining in Mohs micrographic surgery: a review.
El Tal AK; Abrou AE; Stiff MA; Mehregan DA
Dermatol Surg; 2010 Mar; 36(3):275-90. PubMed ID: 20100275
[TBL] [Abstract][Full Text] [Related]
20. Melanomas of the head and neck have high-local recurrence risk features and require tissue-rearranging reconstruction more commonly than basal cell carcinoma and squamous cell carcinoma: A comparison of indications for microscopic margin control prior to reconstruction in 13,664 tumors.
Fix W; Etzkorn JR; Shin TM; Howe N; Bhatt M; Sobanko JF; Miller CJ
J Am Acad Dermatol; 2021 Aug; 85(2):409-418. PubMed ID: 30458206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
